Albumin Fusion Proteins
AssigneesHuman Genome Sciences, Inc., Novozymes Biopharma DK A/S
InventorsDavid J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
Life of this patent
Estimating the term…
Abstract
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acid vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
Claims19
A fusion protein comprising:
- a serum cholinesterase polypeptide fused to an albumin polypeptide, wherein said serum cholinesterase polypeptide comprises a variant of serum cholinesterase, wherein the variant comprises a polypeptide having an amino acid sequence that is at least 90% identical to amino acids 29 to 602 of SEQ ID NO:52;
- and wherein said albumin polypeptide comprises:
- i) a full-length albumin;
- ii) a fragment of albumin;
- iii) a polypeptide consisting of an amino acid sequence at least 95% identical to the sequence set forth as SEQ ID NO:18;
- iv) amino acids 1 to 585 of SEQ ID NO:18;
- v) amino acids 1 to 387 of SEQ ID NO:18;
- vi) amino acids 1 to 194 of SEQ ID NO:18;
- vii) amino acids 195 to 387 of SEQ ID NO:18;
- viii) amino acids 388 to 585 of SEQ ID NO:18;
- ix) amino acids 195 to 585 of SEQ ID NO:18;
- or
- x) amino acids 1 to 194 of SEQ ID NO:18 combined with amino acids 388 to 585 of SEQ ID NO:18
- wherein said fusion protein has serum cholinesterase activity and a prolonged serum half-life compared to the unfused serum cholinesterase polypeptide.
A fusion protein comprising:
- a serum cholinesterase polypeptide fused to an albumin polypeptide, wherein said serum cholinesterase polypeptide comprises a polypeptide having at least 99% sequence identity to amino acids 29 to 557 of SEQ ID NO:52;
- and wherein said albumin polypeptide comprises:
- i) a full-length albumin;
- ii) a fragment of albumin;
- iii) a polypeptide consisting of an amino acid sequence at least 95% identical to SEQ ID NO:
- 18;
- iv) amino acids 1 to 585 of SEQ ID NO:
- 18;
- v) amino acids 1 to 387 of SEQ ID NO:18;
- vi) amino acids 1 to 194 of SEQ ID NO:18;
- vii) amino acids 195 to 387 of SEQ ID NO:18;
- viii) amino acids 388 to 585 of SEQ ID NO:18;
- ix) amino acids 195 to 585 of SEQ ID NO:18;
- or
- x) amino acids 1 to 194 of SEQ ID NO:18 combined with amino acids 388 to 585 of SEQ ID NO:18
- wherein said fusion protein has serum cholinesterase activity and a prolonged serum half-life compared to the unfused serum cholinesterase polypeptide.
A fusion protein comprising a serum cholinesterase polypeptide fused to an albumin polypeptide, wherein said serum cholinesterase polypeptide has an amino acid sequence which is 95% identical to amino acids 29-557 of SEQ ID NO:52, wherein said albumin polypeptide comprises amino acids 1 to 585 of SEQ ID NO:18;
- and wherein the fusion protein has serum cholinesterase activity and a prolonged serum half-life compared to an unfused serum cholinesterase polypeptide.
A fusion protein comprising a serum cholinesterase polypeptide fused to the N-terminus of an albumin polypeptide, wherein the albumin polypeptide has the amino acid sequence set forth in SEQ ID NO:18, and wherein said fusion protein has serum cholinesterase activity and has a prolonged serum half-life compared to an unfused serum cholinesterase polypeptide.
Dependencies are inferred from the claim text.